Methods of treating inflammatory disease using LDHA inhibitors

SK2016-051

Share
Share

SUMMARY OF INVENTION

Aerobic glycolysis, a process by which glucose is metabolized to lactate in the presence of oxygen, is observed under a plethora of physiopathological conditions. Scientists at MSK discovered that the enzyme that catalyzes pyruvate conversion to lactate, lactate dehydrogenase A (LDHA), is specifically induced in T-cells.

By using LDHA inhibitors, inflammatory phenotypes in mice can be corrected, suggesting that these inhibitors could be used to treat inflammation. Dr. Ming and colleagues have demonstrated that different inhibitors may represent a possible therapeutic approach. Their findings reveal an epigenetic mechanism by which aerobic glycolysis promotes effector T-cell differentiation, suggesting that LDHA may be targeted therapeutically in autoinflammatory diseases.

ADVANTAGES

  • Immunologist Ming Li studies mechanisms of immune regulation, and their relevance to diseases including cancer.
  • This invention provides methods for treating or preventing T cell-mediated diseases or disorders through a novel approach, by administering LDHA inhibitors.

MARKET OPPORTUNITIES

LDHA inhibitors can be used in autoimmune diseases and transplant rejection.

AREAS OF APPLICATION

T-cell-mediated diseases or disorders, inflammation

PATENT INFORMATION

US Divisional PCT/US2017/051724 pending.     

REFERENCES

Min Peng et al., Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354(6311):481-484 (2016).

LEAD INVESTIGATOR

Ming Li, PhD, Immunologist and Laboratory Head, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

CONTACT INFORMATION

James Delorme, PhD, Licensing Manager
Tel: 332-229-0588
E-mail: [email protected]
 

Stage of Development

In vitro